HTG Molecular Diagnostics, Inc.
Symbool: HTGM
NASDAQ
0.48
USDMarktprijs vandaag
-0.0745
Koers/Winst Verhouding
-0.0008
Koers/Winst Groei Verhouding
1.06M
MRK Kapitalisatie
- 0.00%
DIV Rendement
HTG Molecular Diagnostics, Inc. (HTGM) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 39.4 | 12.2 | 21.9 | 28.7 | |||||||||||
balance-sheet.row.short-term-investments | 15.23 | 0 | 12.3 | 6.3 | |||||||||||
balance-sheet.row.net-receivables | 4.77 | 1.4 | 2.1 | 1.6 | |||||||||||
balance-sheet.row.inventory | 5.21 | 0.9 | 2 | 1.5 | |||||||||||
balance-sheet.row.other-current-assets | 4.89 | 1.1 | 1.2 | 1.1 | |||||||||||
balance-sheet.row.total-current-assets | 54.94 | 15.7 | 27.2 | 32.9 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 6.65 | 1.6 | 2.5 | 2.2 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 2.88 | 0.5 | 0.8 | 0.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 9.52 | 2.1 | 3.3 | 2.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 64.46 | 17.8 | 30.5 | 35.2 | |||||||||||
balance-sheet.row.account-payables | 4.08 | 1.2 | 1.6 | 1.3 | |||||||||||
balance-sheet.row.short-term-debt | 19.02 | 4.3 | 5.6 | 3.7 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 4.92 | 0.5 | 6.1 | 8.9 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 8.71 | 2.8 | 2.6 | 2 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 20.01 | 4.1 | 10.1 | 13.5 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 3.41 | 1 | 1.4 | 1.1 | |||||||||||
balance-sheet.row.total-liab | 51.81 | 12.4 | 20.1 | 20.7 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -910.86 | -229.9 | -208.3 | -191.2 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.02 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 923.5 | 235.3 | 218.7 | 205.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 12.64 | 5.4 | 10.4 | 14.5 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 64.46 | 17.8 | 30.5 | 35.2 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 12.64 | 5.4 | 10.4 | 14.5 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 64.46 | - | - | - | |||||||||||
Total Investments | 15.23 | 0 | 12.3 | 6.3 | |||||||||||
balance-sheet.row.total-debt | 23.94 | 4.8 | 11.7 | 12.6 | |||||||||||
balance-sheet.row.net-debt | -0.24 | -7.4 | 2.1 | -9.8 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -20.15 | -21.6 | -17.1 | -20.9 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0.49 | 0.6 | 0.7 | 1.3 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -1.4 | 0.7 | |||||||||||
cash-flows.row.stock-based-compensation | 0.68 | 0.8 | 1.4 | 1.8 | |||||||||||
cash-flows.row.change-in-working-capital | -0.16 | -0.1 | -1 | -0.2 | |||||||||||
cash-flows.row.account-receivables | -0.38 | 0.7 | -0.8 | 1.6 | |||||||||||
cash-flows.row.inventory | 0.27 | 0.1 | -1.4 | -0.3 | |||||||||||
cash-flows.row.account-payables | -0.2 | -0.5 | 0.5 | 0 | |||||||||||
cash-flows.row.other-working-capital | 0.16 | -0.4 | 0.7 | -1.5 | |||||||||||
cash-flows.row.other-non-cash-items | 2.31 | 1.9 | 0.9 | 0.9 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -16.83 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.02 | 0 | -0.6 | -0.5 | |||||||||||
cash-flows.row.acquisitions-net | -99828.51 | 0 | -25018 | -72.5 | |||||||||||
cash-flows.row.purchases-of-investments | -11.15 | -7.6 | -18.6 | -12.5 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 14.52 | 19.9 | 12.6 | 31.6 | |||||||||||
cash-flows.row.other-investing-activites | 99828.64 | 0.1 | 25018 | 72.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 3.48 | 12.4 | -6.7 | 18.7 | |||||||||||
cash-flows.row.debt-repayment | -7.16 | -7.8 | -0.8 | -3.6 | |||||||||||
cash-flows.row.common-stock-issued | 2.8 | 1.4 | 10.7 | 7.5 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 6.09 | 15 | 0.5 | 5.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 1.73 | 8.6 | 10.4 | 9 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -11.62 | 2.6 | -12.8 | 11.5 | |||||||||||
cash-flows.row.cash-at-end-of-period | 24.18 | 12.2 | 9.6 | 22.4 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 35.79 | 9.6 | 22.4 | 10.9 | |||||||||||
cash-flows.row.operating-cash-flow | -16.83 | -18.4 | -16.5 | -16.3 | |||||||||||
cash-flows.row.capital-expenditure | -0.02 | 0 | -0.6 | -0.5 | |||||||||||
cash-flows.row.free-cash-flow | -16.85 | -18.4 | -17.2 | -16.7 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 6.21 | 6.4 | 8.9 | 8.5 | |||||||||||
income-statement-row.row.cost-of-revenue | 4.87 | 4.6 | 4.1 | 4 | |||||||||||
income-statement-row.row.gross-profit | 1.35 | 1.8 | 4.8 | 4.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 6.47 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | -0.24 | 0 | -1 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 20.94 | 22.6 | 22.6 | 24.1 | |||||||||||
income-statement-row.row.cost-and-expenses | 25.8 | 27.2 | 26.7 | 28.1 | |||||||||||
income-statement-row.row.interest-income | 0.19 | 0.1 | 0 | 0.3 | |||||||||||
income-statement-row.row.interest-expense | 0.75 | 0.9 | 1.1 | 1 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -0.55 | -0.8 | 0.7 | -1.3 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | -0.24 | 0 | -1 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -0.55 | -0.8 | 0.7 | -1.3 | |||||||||||
income-statement-row.row.interest-expense | 0.75 | 0.9 | 1.1 | 1 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0.55 | 0.7 | -1.7 | 1.6 | |||||||||||
income-statement-row.row.ebitda-caps | -19.29 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -19.59 | -20.8 | -17.8 | -19.6 | |||||||||||
income-statement-row.row.income-before-tax | -20.14 | -21.6 | -17.1 | -20.9 | |||||||||||
income-statement-row.row.income-tax-expense | 0.01 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.net-income | -20.15 | -21.6 | -17.1 | -20.9 |
Vaak gestelde vragen
Wat is HTG Molecular Diagnostics, Inc. (HTGM) totale activa?
HTG Molecular Diagnostics, Inc. (HTGM) totale activa is 17777655.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 3471815.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.184.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -3.020.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -2.946.
Wat is HTG Molecular Diagnostics, Inc. (HTGM) nettowinst (netto-inkomen)?
De nettowinst is -21594476.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 4833948.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 22623682.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 2996409.000.